C12N 15/867
Retroviral vectors
C12N15/867 (Retroviral vectors) appears on 99 US grants and 230 published applications in this corpus.
Search patents in C12N- Granted patents
- 99
- Published applications
- 230
- Assignees
- 155
- Inventors
- 542
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 2 |
| 2004 | 1 | 1 |
| 2005 | 0 | 3 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 1 | 3 |
| 2009 | 0 | 1 |
| 2010 | 2 | 1 |
| 2011 | 3 | 4 |
| 2012 | 0 | 2 |
| 2013 | 4 | 9 |
| 2014 | 4 | 7 |
| 2015 | 6 | 5 |
| 2016 | 3 | 1 |
| 2017 | 5 | 7 |
| 2018 | 7 | 21 |
| 2019 | 6 | 22 |
| 2020 | 9 | 14 |
| 2021 | 10 | 17 |
| 2022 | 9 | 16 |
| 2023 | 8 | 10 |
| 2024 | 6 | 12 |
| 2025 | 8 | 26 |
| 2026 | 7 | 43 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Lentiviral vectors in hematopoietic stem cells to treat Wiskott-Aldrich syndrome (WAS)25 Aug 2026US 12,714,732 B2The Regents of the University of California
- Compositions and methods for hemoglobin production16 Jun 2026US 12,655,446 B2The Children's Hospital of Philadelphia
- CA2-IL15 fusion proteins for tunable regulation2 Jun 2026US 12,642,792 B2Obsidian Therapeutics, Inc.
- Augmentations to lentiviral vectors (CCLC-MGATA/ANK-CORE LCR-BETA-AS3-FB) to increase expression26 May 2026US 12,637,696 B2The Regents of the University of California
- Tethered interleukin-15 and interleukin-215 May 2026US 12,617,833 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Materials and methods for increasing immune responses within a mammal8 Oct 2026US 2026/0306668 A1Mayo Foundation for Medical Education and Research
- Kinetically controlled methods to prepare concentrated shelf-stable nucleic acid transfection vehicles8 Oct 2026US 2026/0308631 A1The Johns Hopkins University
- Click chemistry assisted cell surface engineering for restoring lentivirus entry8 Oct 2026US 2026/0308632 A1The Children’s Hospital of Philadelphia
- Method for modulating the differentiation and functions of human dendritic cells1 Oct 2026US 2026/0297524 A1Centre National De La Recherche Scientifique
- Cell1 Oct 2026US 2026/0297622 A1Antion Biosciences SA
Most cited
By later US patents
- Therapeutic retroviral vectors for gene therapy27US 7,901,671 B2bluebird bio, Inc. · 2011
- Point-of-care and/or portable platform for gene therapy16US 10,350,245 B2Fred Hutchinson Cancer Research Center · 2019
- Lentiviral vectors for the preparation of immunotherapeutical compositions13US 7,968,332 B2Centre National De La Recherche Scientifique · 2011
- Compounds for improved viral transduction13US 9,988,644 B2bluebird bio, Inc. · 2018
- Methods for therapy of neurodegenerative disease of the brain12US 6,815,431 B2The Regents of the University of California · 2004